Drug Trial Radar · NCT06434363
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
47
Planned (sponsor's estimate)
Start
Jul 31, 2024
Primary completion
Dec 31, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease. The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.
Conditions
- Autoimmune Disorders
- Systemic Sclerosis
- Systemic Lupus Erythematosus
- Lupus
- Lupus Nephritis
Interventions
TafasitamabDrug
Given by vein (IV)
Fludarabine phosphateDrug
Given by vein (IV)
CyclophosphamideDrug
Given by vein (IV)
Tafasitamab and NK cellsDrug
Given by vein (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventTime frame: Through study completion; an average of 1 year.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas · Recruiting
The University of Texas Health Science Center at Houston
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.